ATE443699T1 - Pyridine zur behandlung von verletztemsäugetiernervengewebe - Google Patents
Pyridine zur behandlung von verletztemsäugetiernervengewebeInfo
- Publication number
- ATE443699T1 ATE443699T1 AT03796756T AT03796756T ATE443699T1 AT E443699 T1 ATE443699 T1 AT E443699T1 AT 03796756 T AT03796756 T AT 03796756T AT 03796756 T AT03796756 T AT 03796756T AT E443699 T1 ATE443699 T1 AT E443699T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- nerve tissue
- compositions
- treatment
- pyridine
- Prior art date
Links
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 2
- 241000124008 Mammalia Species 0.000 title 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 210000000944 nerve tissue Anatomy 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 150000003222 pyridines Chemical class 0.000 abstract 2
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 abstract 1
- 230000036982 action potential Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000002045 lasting effect Effects 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000005036 nerve Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 210000000278 spinal cord Anatomy 0.000 abstract 1
- 208000037816 tissue injury Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Meat, Egg Or Seafood Products (AREA)
- Devices For Medical Bathing And Washing (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43163702P | 2002-12-06 | 2002-12-06 | |
| PCT/US2003/038834 WO2004052291A2 (en) | 2002-12-06 | 2003-12-05 | Pyridines for treating injured mammalian nerve tissue |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE443699T1 true ATE443699T1 (de) | 2009-10-15 |
Family
ID=32507771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03796756T ATE443699T1 (de) | 2002-12-06 | 2003-12-05 | Pyridine zur behandlung von verletztemsäugetiernervengewebe |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7244748B2 (enExample) |
| EP (1) | EP1567497B1 (enExample) |
| JP (1) | JP4903385B2 (enExample) |
| CN (1) | CN1745064A (enExample) |
| AT (1) | ATE443699T1 (enExample) |
| AU (1) | AU2003298034B2 (enExample) |
| CA (1) | CA2508165C (enExample) |
| DE (1) | DE60329415D1 (enExample) |
| WO (1) | WO2004052291A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8729107B2 (en) * | 2002-12-06 | 2014-05-20 | Purdue Research Foundation | Pyridines for treating injured mammalian nerve tissue |
| FR2849029B1 (fr) | 2002-12-20 | 2005-03-18 | Lafon Labor | Procede de preparation et formes cristallines des enantiomeres optiques du modafinil. |
| WO2007061554A2 (en) * | 2005-10-21 | 2007-05-31 | Purdue Research Foundation | Dosage of 4-aminopyridine derivatives for treatment of central nervous system injuries |
| US8066306B1 (en) | 2008-07-18 | 2011-11-29 | Chicago Tag & Label, Inc. | Label sheet with wristband |
| US8181994B1 (en) | 2008-07-18 | 2012-05-22 | Chicago Tag & Label, Inc. | Sheet with wristband |
| WO2012009204A1 (en) * | 2010-07-15 | 2012-01-19 | The Trustees Of Columbia University In The City Of New York | Methods for diagnosing and treating concussive disorders |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| WO2013173746A2 (en) | 2012-05-17 | 2013-11-21 | The University Of Chicago | Use of fluorinated derivatives of 4-aminopyridine in therapeutics and medical imaging |
| US9617215B2 (en) | 2012-05-17 | 2017-04-11 | The University Of Chicago | Use of fluorinated derivatives of 4-aminopyridine in therapeutics and medical imaging |
| CN102702261A (zh) * | 2012-05-29 | 2012-10-03 | 南京信息工程大学 | 制备1-取代苯基-4-乙氧羰基-5-( 二苯基膦氧)氨基-1 ,2 ,3-三唑的方法 |
| SI2861595T1 (sl) | 2012-06-13 | 2017-04-26 | Incyte Holdings Corporation | Substituirane triciklične spojine kot inhibitorji fgfr |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| LT2986610T (lt) | 2013-04-19 | 2018-04-10 | Incyte Holdings Corporation | Bicikliniai heterociklai, kaip fgfr inhibitoriai |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| SG10201913036RA (en) | 2015-02-20 | 2020-02-27 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| KR20210018264A (ko) | 2018-05-04 | 2021-02-17 | 인사이트 코포레이션 | Fgfr 억제제의 염 |
| PL3788047T3 (pl) | 2018-05-04 | 2025-04-14 | Incyte Corporation | Stałe postacie inhibitora fgfr i sposoby ich otrzymywania |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CR20220169A (es) | 2019-10-14 | 2022-10-27 | Incyte Corp | Heterociclos bicíclicos como inhibidores de fgfr |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| JP7720840B2 (ja) | 2019-12-04 | 2025-08-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式複素環 |
| AU2020395185A1 (en) | 2019-12-04 | 2022-06-02 | Incyte Corporation | Derivatives of an FGFR inhibitor |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| EP4352060A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1071035A (en) * | 1964-09-02 | 1967-06-07 | Rech Et Pharmacologie | Improvements in and relating to new carbamates and thiocarbamates and the process of preparation and therapeutic applications thereof |
| US3433873A (en) * | 1966-04-05 | 1969-03-18 | Phillips Petroleum Co | Compositions and methods for controlling birds |
| US3804844A (en) * | 1970-12-02 | 1974-04-16 | Dow Chemical Co | Process for preparing pyridylcarbamates |
| GB1339764A (en) * | 1971-03-29 | 1973-12-05 | Ici Ltd | Pyridine derivatives |
| IL39094A (en) * | 1971-04-21 | 1976-05-31 | Ciba Geigy Ag | 7-(aminopyridiniumacetyl)-3-heterocyclylthiomethyl-cephalosporanic acid derivatives,their manufacture and pharmaceutical compositions containing them |
| SU464177A1 (ru) * | 1973-01-08 | 1978-03-25 | Донецкое Отделение Физико-Органической Химии Института Физической Химии Ан Украинской Сср | Способ получени 4-галоидзамещенных имидазо- (4,5-с)-пиридин -2-она |
| US3995042A (en) * | 1973-09-07 | 1976-11-30 | E. R. Squibb & Sons, Inc. | Pyridine containing compounds |
| US4304911A (en) * | 1980-11-19 | 1981-12-08 | Sterling Drug Inc. | Benzoylphenyl lower alkanoyl piperidines |
| FR2624699B1 (fr) * | 1987-12-18 | 1990-04-13 | Bernard Lyon I Universite Clau | Derives heterocycliques de n-carbamoyl-, n-thiocarbamoyl- ou n-amidino-glycine ou beta-alanine utiles comme agents edulcorants |
| JPH03181462A (ja) * | 1989-12-08 | 1991-08-07 | Nippon Kayaku Co Ltd | Ｎ―（４―ピリジル）カーバメート誘導体およびそれを有効成分とする開花促進剤 |
| IE82916B1 (en) * | 1990-11-02 | 2003-06-11 | Elan Corp Plc | Formulations and their use in the treatment of neurological diseases |
| EP1063291A3 (en) * | 1992-09-25 | 2001-04-25 | Synaptic Pharmaceutical Corporation | DNA encoding human alpha 1 adrenergic receptors and uses thereof |
| CA2085785C (en) * | 1992-12-18 | 2005-03-15 | Robert R. Hansebout | The use of 4-aminopyridine in the treatment of a neurological condition |
| US5502498A (en) | 1993-03-10 | 1996-03-26 | Samsung Electronics Co., Ltd. | Clamp signal generation-control circuit and a method therefor |
| JP2809883B2 (ja) * | 1994-09-22 | 1998-10-15 | ユコン リミテッド | 新規のカルバメート化合物及びその製造方法 |
| JP3583489B2 (ja) * | 1994-12-22 | 2004-11-04 | 日清紡績株式会社 | カルボジイミド誘導体 |
| EP0822930B1 (en) * | 1995-04-28 | 1999-07-28 | Kumiai Chemical Industry Co., Ltd. | Pyridine derivative and pesticide |
| US5880128A (en) * | 1996-05-08 | 1999-03-09 | Schering Corporation | Carbonyl piperazinyl and piperidinyl compounds |
| AU719333B2 (en) * | 1996-10-07 | 2000-05-04 | Ortho-Mcneil Pharmaceutical, Inc. | 5-heteroatom-containing alkyl substituted-3-oxo-p yrido(1,2-a) benzimidazole-4-carboxamide derivatives useful in treating central nervous system disorders |
| US5961309A (en) * | 1997-04-24 | 1999-10-05 | Trw Inc. | Gear pump with noise attenuation |
| JP2001519350A (ja) * | 1997-10-07 | 2001-10-23 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | ナフト−イミダゾ［１，２−ａ］ピリジン誘導体、その製造及び中枢神経系障害の処置におけるその使用 |
| US6632823B1 (en) * | 1997-12-22 | 2003-10-14 | Merck & Co., Inc. | Substituted pyridine compounds useful as modulators of acetylcholine receptors |
| AUPP150098A0 (en) * | 1998-01-27 | 1998-02-19 | Fujisawa Pharmaceutical Co., Ltd. | Benzamide derivatives |
| ATE430149T1 (de) * | 1998-03-04 | 2009-05-15 | Bristol Myers Squibb Co | Heterocyclen substituierte imidazopyrazine als protein- tyrosin-kinase-inhibitoren |
| ATE258934T1 (de) * | 1998-10-30 | 2004-02-15 | Lilly Co Eli | Azaindol derivate und ihre verwendung als antithrombotische wirkstoffe |
| DE60014216T2 (de) * | 1999-02-24 | 2006-03-02 | F. Hoffmann-La Roche Ag | 4-Phenylpyridinderivate und deren Verwendung als NK-1 Rezeptorantagonisten |
| WO2000050400A1 (en) * | 1999-02-25 | 2000-08-31 | Pfizer Products Inc. | 2-aminopyridines containing fused ring substituents |
| AU4007900A (en) * | 1999-03-11 | 2000-10-16 | Neurogen Corporation | Aryl fused 2,4-disubstituted pyridines: nk3 receptor ligands |
| EP1208097B1 (en) * | 1999-07-28 | 2009-02-18 | Aventis Pharmaceuticals Inc. | Substituted oxoazaheterocyclyl compounds |
| US6495550B2 (en) * | 1999-08-04 | 2002-12-17 | Icagen, Inc. | Pyridine-substituted benzanilides as potassium ion channel openers |
| AU2155001A (en) * | 1999-11-10 | 2001-06-06 | Aventis Pharma Deutschland Gmbh | N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor xa |
| FR2806722B1 (fr) * | 2000-03-23 | 2002-05-17 | Sanofi Synthelabo | Derives de n-(heterocyclylbutyl) benzene-ou pyridine sulfonamide, leur preparation et leur application en therapeutique |
| US20020045613A1 (en) * | 2000-04-27 | 2002-04-18 | Heinz Pauls | 1-aroyl-piperidinyl benzamidines |
| DE10063294A1 (de) * | 2000-12-19 | 2002-07-04 | Aventis Pharma Gmbh | Substituierte Heterocyclo-Norbornylamino-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| CA2448561C (en) * | 2001-05-31 | 2011-07-19 | Sanofi-Synthelabo | Aminoquinoline derivatives and their use as adenosine a3 ligands |
| JP2003073357A (ja) * | 2001-09-03 | 2003-03-12 | Mitsubishi Pharma Corp | アミド化合物を含有するＲｈｏキナーゼ阻害剤 |
| TWI317360B (en) * | 2001-11-07 | 2009-11-21 | Schering Corp | Heteroaryl derivatives as superior ligands for nociceptin receptor orl-1 |
-
2003
- 2003-12-05 US US10/730,495 patent/US7244748B2/en not_active Expired - Fee Related
- 2003-12-05 CA CA2508165A patent/CA2508165C/en not_active Expired - Fee Related
- 2003-12-05 WO PCT/US2003/038834 patent/WO2004052291A2/en not_active Ceased
- 2003-12-05 JP JP2004559375A patent/JP4903385B2/ja not_active Expired - Fee Related
- 2003-12-05 EP EP03796756A patent/EP1567497B1/en not_active Expired - Lifetime
- 2003-12-05 AU AU2003298034A patent/AU2003298034B2/en not_active Ceased
- 2003-12-05 CN CNA2003801094006A patent/CN1745064A/zh active Pending
- 2003-12-05 DE DE60329415T patent/DE60329415D1/de not_active Expired - Lifetime
- 2003-12-05 AT AT03796756T patent/ATE443699T1/de not_active IP Right Cessation
-
2007
- 2007-07-16 US US11/778,524 patent/US8097638B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP4903385B2 (ja) | 2012-03-28 |
| EP1567497B1 (en) | 2009-09-23 |
| CA2508165C (en) | 2014-05-06 |
| DE60329415D1 (de) | 2009-11-05 |
| EP1567497A2 (en) | 2005-08-31 |
| US20080039490A1 (en) | 2008-02-14 |
| CN1745064A (zh) | 2006-03-08 |
| AU2003298034A1 (en) | 2004-06-30 |
| WO2004052291A3 (en) | 2004-10-14 |
| US7244748B2 (en) | 2007-07-17 |
| CA2508165A1 (en) | 2004-06-24 |
| JP2006515585A (ja) | 2006-06-01 |
| AU2003298034B2 (en) | 2011-04-21 |
| WO2004052291A2 (en) | 2004-06-24 |
| EP1567497A4 (en) | 2006-11-15 |
| US8097638B2 (en) | 2012-01-17 |
| US20040171587A1 (en) | 2004-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE443699T1 (de) | Pyridine zur behandlung von verletztemsäugetiernervengewebe | |
| WO2007061554A3 (en) | Dosage of 4-aminopyridine derivatives for treatment of central nervous system injuries | |
| DE60045751D1 (de) | Therapeutische Behandlung androgenrezeptorbedingter Leiden | |
| PH12020551038A1 (en) | Compositions comprising co-selected microbiota and methods for use thereof | |
| EA201691260A1 (ru) | ВАРИАНТЫ, ПРОИСХОДЯЩИЕ ИЗ ActRIIB, И ИХ ПРИМЕНЕНИЕ | |
| SE9803710D0 (sv) | Use of certain drugs for treating nerve root injury | |
| CY1119480T1 (el) | Παραγωγα ρετιναλης και μεθοδοι για τη χρηση αυτων για τη θεραπευτικη αντιμετωπιση διαταραχων της ορασης | |
| DE60029799D1 (de) | Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe | |
| EA200500169A1 (ru) | Замещенные производные 1,3-дифенилпроп-2-ен-1-она, получение и применение | |
| MY148985A (en) | 2-aminopyridine analogs as glucokinase activators | |
| TR200002784T2 (tr) | Tip 5 ve tip 3 17beta-Hidroksisteroid dehidrojenaz inhibitörleri ve bunların kullanımı için metodlar | |
| ATE528002T1 (de) | Pyridoncarboxamidderivate zur behandlung hyperproliferativer und angiogenese-vermittelter leiden | |
| ATE222488T1 (de) | Verwendung von anti-vegf-mitteln zur behandlung der endometriose | |
| ATE486606T1 (de) | Therapeutische mittel zum targeting des ncca-atp- kanals und verwendungsverfahren dafür | |
| BR0012175A (pt) | Antagonistas de receptor de igiur5, seletivos para o tratamento de enxaqueca | |
| ATE238792T1 (de) | Verwendung von makroliden zur behandlung von glaukom | |
| Tremblay et al. | Kinesio-taping application and corticospinal excitability at the ankle joint | |
| Yi et al. | Neuromuscular structure of the tibialis anterior muscle for functional electrical stimulation | |
| DE60008143D1 (de) | Lipoxin-a4 und deren analoge zur behandlung von trockenen augen | |
| ATE487484T1 (de) | Therapeutische mittel zum targeting des nc ca-atp-kanals und verwendungsverfahren dafür | |
| NO20081149L (no) | Fremgangsmate for behandling av B-celle-maligniteter ved bruk av TACI-IG fusjonsmolekyl | |
| ATE356995T1 (de) | Verfahren zur identifizierung von mitteln zur behandlung von diabetes | |
| EA201000630A1 (ru) | Применение бензоконденсированных гетероциклических сульфамидных производных для понижения уровней липидов в крови | |
| MXPA03011270A (es) | Uso de antagonistas rank para tratar cancer. | |
| ATE313561T1 (de) | Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |